RTG Mining Stock (OTC:RTTGF), Trade Ideas

RTG Mining Inc is into the mining and exploration business. It is focused on high-grade, low operating cost gold projects. Some of its minor exploration and evaluation assets are held in Africa, all of the company's other assets are located in the Philippines. The organization's principal asset and focus are the Mabilo Project located in Camarines Norte Province, Eastern Luzon, Philippines. The company's other projects include The Bunawan project and the Nalesbitan Project.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACGX

ACRGF

ADOM

ASTVF

AVGR

AVNS

AWLCF

BHRB

BREW

BUDZ

CARB

CDSG

CDTI

CHKR

CHMI

CLSD

CRUUF

CRXPF

CTST

CVALF

DGLY

EONGY

FARM

FFXDF

FNJN

FRRSF

FTPLF

GGISF

GLAPY

GREEN SPIRIT INDUSTRIES by Green Spirit Industries Inc.

GSRX

HIGHCOM GLOBAL SEC by HighCom Global Security, Inc.

HCGS

HEMP

HIMX

HLUYY

HOPS

IDCBF

IMLFF

IMTL

JAPAY

KPCUF

KZMYY

LBRT

LTRPA

MALRY

MMSI

MRPLY

MINEWORX TECH LTD ORD by Mineworx Technologies Ltd.

MWXRF

NMTC

OWCP

OXBDF

PBBSF

PHVAF

POLA

QADA

QADB

RGNX

RRRLF

RTRX

RTTGF

RXMD

SAABY

SALM

SHTLF

SHZUY

SILLF

SLGWF

SMLP

SNPW

SOUHY

TECK

THDDY

TOPS

VATE

VIVO

VREOF

XENT

PGUUF

HUTCY

SLNTY

Stocks That Hit 52-Week Lows On Thursday

RTG Mining Inc

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor &nbsp;
Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful

Biotech

SCPH

scPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection

Analysts' ratings for Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $147.0, a high estimate of $155.00, and a low estimate of $135.00. This current average has increased by 0.22% from the previous average price target of $146.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1713960066_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Quest Diagnostics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$155.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Quest Diagnostics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Quest Diagnostics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Quest Diagnostics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Quest Diagnostics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DGX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Quest Diagnostics analyst ratings.</a>
<h2>Discovering Quest Diagnostics: A Closer Look</h2>
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
<h3>Quest Diagnostics's Economic Impact: An Analysis</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Negative Revenue Trend: Examining Quest Diagnostics's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -1.93% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Quest Diagnostics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 8.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.02%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.4%, the company showcases effective utilization of assets.
Debt Management: Quest Diagnostics's debt-to-equity ratio is below the industry average at 0.87, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Landscape: 5 Takes On Quest Diagnostics

Analysts' ratings for Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) over the last quarter vary from bullish to bearish, as provided by 13 analysts.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $586.0, a high estimate of $621.00, and a low estimate of $547.00. Witnessing a positive shift, the current average has risen by 2.11% from the previous average price target of $573.89.
<img src="https://www.benzinga.com/files/images/story/2024/1713960057_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Elevance Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$585.00</td>
<td>$575.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$574.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$605.00</td>
<td>$585.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$557.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$604.00</td>
<td>$602.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$621.00</td>
<td>$584.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$580.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$557.00</td>
<td>$561.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$580.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$584.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$580.00</td>
<td>$547.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$547.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Elevance Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Elevance Health compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Elevance Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Elevance Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Elevance Health analyst ratings.</a>
<h2>Delving into Elevance Health's Background</h2>
Elevance Health remains one of the leading health insurers in the U.S., providing medical benefits to 47 million medical members as of December 2023. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs such as Medicaid and Medicare Advantage plans, too.
<h3>A Deep Dive into Elevance Health's Financials</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Elevance Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.96% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.28%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Elevance Health's ROE excels beyond industry benchmarks, reaching 5.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Elevance Health's ROA stands out, surpassing industry averages. With an impressive ROA of 2.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.65, caution is advised due to increased financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Decoding 13 Analyst Evaluations For Elevance Health

Throughout the last three months, 21 analysts have evaluated Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $153.33, a high estimate of $200.00, and a low estimate of $110.00. This current average reflects an increase of 12.23% from the previous average price target of $136.62. 
<img src="https://www.benzinga.com/files/images/story/2024/1713960040_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Airbnb. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Lee</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$160.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Announces</td>
<td>Buy</td>
<td>$190.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Naved Khan</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$127.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$168.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$143.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$135.00</td>
<td>$134.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$150.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Neutral</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Ju</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Scott Devitt</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Mario Lu</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Airbnb. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Airbnb compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Airbnb's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Airbnb's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABNB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Airbnb analyst ratings.</a>
<h2>Unveiling the Story Behind Airbnb</h2>
Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered 7.7 million active accommodation listings as of Dec. 31, 2023. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.
<h3>Airbnb's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Airbnb displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 16.61%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Airbnb's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -15.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Airbnb's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.04%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Airbnb's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.66%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABNB

Analyst Ratings For Airbnb

Ratings for Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $71.25, with a high estimate of $78.00 and a low estimate of $59.00. This current average reflects an increase of 8.78% from the previous average price target of $65.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1713960025_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Enova International by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$78.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>James Fotheringham</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$59.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$73.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Enova International. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Enova International compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Enova International's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Enova International's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ENVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enova International analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Enova International</h2>
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and the United Kingdom. Consumers apply for credit online, receive a decision almost immediately, and can receive funds within one day. Enova acts as either the lender or a third-party facilitator between borrowers and other lenders. The company earns revenue from interest income, finance charges, and other fees, including fees on the transactions between borrowers and third-party lenders. The majority of revenue comes from the United States. The company realizes similar amounts of revenue from each of its three different products: short-term loans, lines of credit, and installment loans.
<h3>Financial Insights: Enova International</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Enova International's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 20.04%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Enova International's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.96%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.78%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Enova International's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.8%, the company showcases efficient use of assets and strong financial health.
Debt Management: Enova International's debt-to-equity ratio is below the industry average at 2.4, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENVA

Expert Outlook: Enova International Through The Eyes Of 4 Analysts

Truist Securities analyst William Stein maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Hold and lowers the price target from $176 to $162.

Price Target

TSLA

Truist Securities Maintains Hold on Tesla, Lowers Price Target to $162

WIIM

Equinox Gold shares are trading lower after the company announced that it entered into a binding share purchase agreement with funds managed by Orion Mine Financing Management to acquire 40% interest in Greenstone Gold Mine GP.

Truist Securities analyst William Stein maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Hold and raises the price target from $165 to $167.

Truist Securities Maintains Hold on Texas Instruments, Raises Price Target to $167

Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) reported upbeat earnings for its fiscal <a href="https://www.benzinga.com/news/earnings/24/04/38377703/spotify-surpasses-q1-earnings-and-revenue-estimates">first quarter 2024 on Tuesday</a>.
The company posted revenue growth of 20% year-on-year to $3.95 billion (3.64 billion euros), beating the consensus of $3.85 billion. EPS of $1.05 (97 cents) beat the consensus of 70 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Premium Revenue grew 20% year over year to 3.25 billion euros, helped by subscriber additions and ARPU increases. Total MAUs (Monthly Active Users) rose 19% Y/Y to 615 million , which missed its guidance by 3 million.
Ad-supported MAUs grew 22% Y/Y to 388 million. Premium Subscribers grew 14% Y/Y to 239 million.
Spotify held 4.7 billion euros in cash and equivalents and generated €207 million in free cash flow.
Spotify said it expects second-quarter revenue of 3.8 billion euros (consensus $3.76 billion) and total MAUs of 631 million.
Spotify shares rose 11.4% to close at $303.31 on Tuesday.
These analysts made changes to their price targets on Spotify following earnings announcement.
<ul>
<li>Pivotal Research boosted the price target on Spotify from $390 to $400. Pivotal Research analyst Jeffrey Wlodarczak maintained a Buy rating.</li>
<li>Benchmark raised the price target on Spotify from $325 to $375. Benchmark analyst Matthew Harrigan maintained a Buy rating.</li>
<li>Rosenblatt increased the price target on Spotify from $315 to $396. Rosenblatt analyst Barton Crockett maintained a Buy rating.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38396543/meta-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-streets-mos">Meta Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>

Earnings

SPOT

Spotify Analysts Boost Their Forecasts After Q1 Earnings

SYRA

Syra Health Announced That It Has Been Selected By The City Of Portland In Maine For Developing A Health Equity Accelerator Plan To Address Social Determinants Of Health In The Greater Portland Community

Under the terms of the SPA, Equinox Gold will pay $995 million to acquire Orion's 40% interest in Greenstone, payable as follows:
<ul>
<li>42.0 million common shares of Equinox Gold valued at $250 million;</li>
<li>$705 million in cash payable on closing; and</li>
<li>$40 million in cash payable by December 31, 2024. &nbsp;</li>
</ul>
Equinox Gold will fund the cash consideration with net proceeds from both a new $500 million three-year term loan and a bought deal equity financing of common shares of Equinox Gold for approximately $260 million.

Equinox Gold On April 23 Said It Will Acquire Orion Mine Finance Management's 40% Interest In Greenstone Gold Mine GP; Equinox Gold To Pay $995M

Wedbush analyst Matt Bryson reiterates Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Neutral and maintains $530 price target.

Reiteration

SMCI

Wedbush Reiterates Neutral on Super Micro Computer, Maintains $530 Price Target

Mizuho analyst Vijay Rakesh maintains Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Neutral and raises the price target from $164 to $170.

Mizuho Maintains Neutral on Texas Instruments, Raises Price Target to $170

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has introduced a new, Performance edition of <a href="https://www.benzinga.com/news/24/02/36921718/youtuber-marques-brownlee-reviews-refreshed-model-3-calls-it-teslas-most-important-car-i-am-impresse">the refreshed Model 3</a> in the U.S., priced at $52,990, higher than its Model Y counterpart. 
What Happened: The new Model 3 performance is now available on the website priced at $52,990, higher than its rear-wheel drive and long-range versions, as well as the Model Y Performance. However, unlike the other two versions of Model 3, the Performance variant is eligible for a $7,500 federal EV tax credit, taking the effective price for eligible buyers down to $45,490. 
The Performance version has a range of 296 miles and a top speed of 163 mph. On ordering the vehicle now, customers can take delivery within the next two months. 
The Refresh: Tesla unveiled the refreshed Model 3 in the U.S. in January. The company listed two variants of the car, namely the rear-wheel drive and long-range. The Performance variant, however, was no longer listed.
However, later in January, Tesla's head of Investor Relations&nbsp;Martin Viecha&nbsp;confirmed the release of a&nbsp;<a href="https://www.benzinga.com/news/24/01/36570546/you-can-finally-order-teslas-new-model-3-in-america-heres-its-starting-price" target="_blank" rel="noreferrer noopener">refreshed Model 3 Performance variant</a>.
&#8220;You should get the Performance one, once that comes out,&#8221; Viecha wrote to television presenter&nbsp;James May&nbsp;who had recently bought a new Model 3.
Tax Credit Confusions: While the Performance is the priciest version of the Model 3, the availability of tax credit on it brings down the effective price of the vehicle for eligible customers below the Long Range. 
But if the customer chooses to lease a Model 3 rear-wheel drive or Long Range instead of buying it, they can avail a $7,500 EV lease incentive distributed over a 24-month or 36-month lease term, making the cost of leasing a Long Range again cheaper than leasing a Performance. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td></td>
<td>Prices Without Tax Credit</td>
<td>Prices After Tax Credit</td>
<td>Monthly Lease Amount </td>
</tr>
<tr>
<td>Model 3 Rear-Wheel Drive</td>
<td>$38,990</td>
<td>$38,990</td>
<td>$299</td>
</tr>
<tr>
<td>Model 3 Long Range</td>
<td>$47,740</td>
<td>$47,740</td>
<td>$439</td>
</tr>
<tr>
<td>Model 3 Performance</td>
<td>$52,990</td>
<td>$45,490</td>
<td>$549</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Prices as provided on Tesla website</figcaption></figure>
Musk on Tuesday said in an X post that the criteria for EV incentives under the Inflation Reduction Act (IRA) have made it all very &#8220;confusing.&#8221; During the company&#8217;s first-quarter earnings call later in the day, Musk also mocked the name of the act, saying it sounds similar to the Irish Republican Army or the Internet Research Agency from Russia.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">To add to the confusion, the IRA credit &#x2A;does&#x2A; apply to a leased Model 3 long range, which is why the lease price is lower than a Model 3 Performance
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1782820855350980924?ref_src=twsrc%5Etfw">April 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/mobility" rel="noreferrer noopener">following this link</a>.
Read More:&nbsp;<a href="https://www.benzinga.com/news/24/04/38397845/tesla-will-solve-autonomy-even-if-i-got-kidnapped-by-aliens-tomorrow-says-elon-musk-as-he-reveals-ta">Tesla Will Solve Autonomy &#8216;Even If I Got Kidnapped By Aliens Tomorrow,&#8217; Says Elon Musk As He Reveals Talks With &#8216;Major Automaker&#8217; For FSD Licensing</a>
Photo via Shutterstock

Tech

Tesla's New $53K Model 3 Performance Eligible For Full Tax Credits, But Leasing Long Range Might Be Cheaper

Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Buy and raises the price target from $150 to $155.

Mizuho Maintains Buy on Quest Diagnostics, Raises Price Target to $155

Rosenblatt analyst Blair Abernethy maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Neutral and maintains $225 price target.

MANH

Rosenblatt Maintains Neutral on Manhattan Associates, Maintains $225 Price Target

Wedbush analyst Richard Anderson reiterates Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) with a Outperform and maintains $140 price target.

Wedbush Reiterates Outperform on Alexandria Real Estate, Maintains $140 Price Target

<a href="https://www.sec.gov/Archives/edgar/data/1849635/000114036124021595/ny20026576x11_ex99-1.htm" title="https://www.sec.gov/Archives/edgar/data/1849635/000114036124021595/ny20026576x11_ex99-1.htm">https://www.sec.gov/Archives/edgar/data/1849635/000114036124021595/ny20026576x11_ex99-1.htm</a>

Legal

Trump Media & Technology Group Sent Letter To House Committees Regarding Potential Stock Manipulation

Wedbush analyst David Chiaverini reiterates Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) with a Neutral and maintains $17 price target.

HAFC

Wedbush Reiterates Neutral on Hanmi Financial, Maintains $17 Price Target

The introduction of Intel&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) newest artificial intelligence chip, Gaudi 3, is projected to benefit three global semiconductor companies significantly.
What Happened: According to Morgan Stanley, TSMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), Alchip (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALCPF#OTC">ALCPF</a>) and Wistron (OTC:<a class="ticker" href="https://www.benzinga.com/stock/WICOF#OTC">WICOF</a>) stand to gain the most from the demand for Intel&#8217;s latest AI chip, CNBC <a href="http://cnbc.com/2024/04/24/morgan-stanley-says-these-3-global-stocks-will-benefit-from-intels-new-ai-chip.html">reported</a> on Tuesday. The financial institution anticipates that Intel&#8217;s supply issues will be resolved in the second half of 2024, leading to a surge in confirmed sales.
TSMC will be responsible for the fabrication of Gaudi 3 chips using its latest-generation 5-nanometer process. Alchip is expected to provide design services for both Gaudi 2 and Gaudi 3, while Wistron is predicted to be the primary baseboard supplier.
Charlie Chan and his team at Morgan Stanley forecast that the total Gaudi shipment volume could hit 300-400k units in 2025, generating $2-3bn revenue for Intel. The investment bank also reiterated its overweight rating on Alchip and TSMC, considering them long-term winners in AI semiconductor demand.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38372445/cathie-woods-ark-invest-says-bitcoin-could-be-priming-for-over-3-000-rally-over-nex?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood&#8217;s Ark Invest Says Bitcoin Could Be Priming For Over 3,000% Rally Over Next 12 Months As King Crypto Becomes Less Inflationary Than Gold After Halving</a>
Why It Matters: The <a href="https://www.benzinga.com/24/04/38362650/tsmc-topped-estimates-on-the-back-of-insatiable-ai-demand">insatiable demand for AI</a> has already propelled TSMC&#8217;s net revenue growth by 16.5% YoY in Q1 2024. The company&#8217;s broad customer base, including AI chip leader NVIDIA and tech giant Apple, is expected to drive further growth.
Earlier this year, <a href="https://www.benzinga.com/markets/asia/24/02/37254196/taiwanese-chip-firms-flock-to-japan-as-china-decoupling-accelerates">Alchip relocated its research and development</a> roles from China to Japan, indicating a strategic shift in the global semiconductor industry. The company&#8217;s anticipated involvement in the design of Intel&#8217;s Gaudi chips aligns with this expansion strategy.
Intel&#8217;s stock has been consolidating since October 2023, with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38355764/intels-inventory-issues-redditors-highlight-how-overstock-killed-their-margins-yet-">Reddit users speculating about its undervaluation</a>. The launch of the Gaudi 3 chip could potentially boost Intel&#8217;s stock value, especially if supply constraints are resolved as predicted.
Price Action: As of Tuesday, Intel&#8217;s stock closed 0.41% at $34.27, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38356886/s-p-500-trades-at-two-month-low-where-is-the-next-support?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">S&amp;P 500 Trades At Two-Month Low: Where Is The Next Support?</a>
Photo via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Analyst Color

Equities

ALCPF

INTC

WICOF

Move Over Nvidia: Experts Bullish On Intel's AI Chip, Predict Surge In These Three Global Stocks

Press Releases

Memorandum of Agreement Signed with TVI Resource Development (Phils.) Inc.

A$14m Raised in Private Placement Announcement to The Toronto Stock Exchange and Australian Stock Exchange 4 July 2023

RTG Mining Inc. Announces Issue of A$10 million Chess Depository Instruments Under Private Placement

Long Form Documentation Now Finalised and Executed for Mabilo Restructure

Mabilo Project Moves From Corporate to Operational Focus

Offerings

RTG Mining Inc. Announces Issue of a $3.8 Million Chess Depository Instruments Under Tranche 2 of Private Placement